Preventing VTE in Outpatients With Cancer
- PMID: 22796860
- PMCID: PMC3418862
- DOI: 10.1378/chest.12-0423
Preventing VTE in Outpatients With Cancer
Conflict of interest statement
Comment on
-
Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.Chest. 2012 Feb;141(2 Suppl):e195S-e226S. doi: 10.1378/chest.11-2296. Chest. 2012. PMID: 22315261 Free PMC article.
References
-
- Amir E, Seruga B, Niraula S, Carlsson L, Ocaña A. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. J Natl Cancer Inst. 2011;103(17):1299-1309 - PubMed
-
- Hurwitz HI, Saltz LB, Van Cutsem E, et al. Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies. J Clin Oncol. 2011;29(13):1757-1764 - PubMed
-
- Khorana AA. Risk assessment and prophylaxis for VTE in cancer patients. J Natl Compr Canc Netw. 2011;9(7):789-797 - PubMed
-
- Graham R, Mancher M, Wolman DM, Greenfield S, Steinberg E, eds; Committee on Standards for Developing Trustworthy Clinical Practice Guidelines ; Board on Health Care Services ; Institute of Medicine of the National Academies Clinical Practice Guidelines We Can Trust. Washington, DC: National Academies Press; 2011 - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
